Literature DB >> 17168433

Primary glioblastoma multiforme in younger patients: a single-institution experience.

Cüneyt Ulutin1, Merdan Fayda, Gorkem Aksu, Oguz Cetinayak, Okan Kuzhan, Fatih Ors, Murat Beyzadeoglu.   

Abstract

AIMS AND
BACKGROUND: To report our experience of patients with primary glioblastoma multiforme of young age by evaluating the characteristics, prognostic factors, and treatment outcomes. PATIENTS AND METHODS: Seventy patients with primary glioblastoma multiforme (GBM) treated at our department between 1996 and 2004 were studied. The male-female ratio was 2.6:1. The median age was 53 (16-74). Sixty-eight patients (97%) were operated on before radiotherapy and 2 patients (3%) underwent only stereotactic biopsy. All patients received radiotherapy. Postoperative chemotherapy as an adjuvant to radiotherapy was given to 9 patients (12%). The patients were divided into 2 groups according to their age (group A < or = 35 years, n = 21 vs group B > 35 years, n = 49). Survival was determined with the Kaplan-Meier method and differences were compared using the log-rank test. Cox regression analysis was performed to identify the independent prognostic factors. Karnofsky performance status (> or = 70 vs < 70), age (< or = 35 vs > 35 years), gender, tumor size (< or = 4 vs > 4 cm), number of involved brain lobes (1 vs more than 1), type of surgery (total vs subtotal), preoperative seizure history (present vs absent), radiotherapy field (total cranium vs partial), total radiotherapy dose (60 vs 66 Gy), and adjuvant chemotherapy (present vs absent) were evaluated in univariate analysis.
RESULTS: The median survival was 10.3 months in the whole group, 19.5 months in the younger age group and 5.7 months in the older age group. During follow-up re-craniotomy was performed in 2 patients (3%), and 1 patient (1%) developed spinal seeding metastases and was given spinal radiotherapy. In univariate analysis younger age vs older age: median 19.5 months vs 5.27 months (P = 0.0012); Karnofsky performance status > or = 70 vs < 70: median 15.3 months vs 2.67 months (P < 0.0001), and external radiotherapy dose 60 Gy vs 66 Gy: median 11.6 months vs 3 months (P = 0.02) were found as significant prognostic factors for survival. In regression analysis a worse performance status (KPS <70) was found to be the only independent factor for survival (P = 0.014, 95% CI HR = 0.0043 [0.0001-0.15]).
CONCLUSIONS: Younger patients with primary glioblastoma multiforme had a relatively long survival (median, 19.5 months, with a 2-year survival rate of 30%) compared to older patients. This was due particularly to their better performance status.

Entities:  

Mesh:

Year:  2006        PMID: 17168433     DOI: 10.1177/030089160609200507

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  9 in total

1.  Morphological characteristics of brain tumors causing seizures.

Authors:  Jong Woo Lee; Patrick Y Wen; Shelley Hurwitz; Peter Black; Santosh Kesari; Jan Drappatz; Alexandra J Golby; William M Wells; Simon K Warfield; Ron Kikinis; Edward B Bromfield
Journal:  Arch Neurol       Date:  2010-03

2.  Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison.

Authors:  Malika L Siker; Meihua Wang; Kimberly Porter; Diana F Nelson; Walter J Curran; Jeff M Michalski; Luis Souhami; Arnab Chakravarti; W K Alfred Yung; John Delrowe; Christopher T Coughlin; Minesh P Mehta
Journal:  J Neurooncol       Date:  2011-01-09       Impact factor: 4.130

3.  Rapid progression of glioblastoma multiforme: A case report.

Authors:  Yan Yan Zhang; Ling Xiang Ruan; Sheng Zhang
Journal:  Oncol Lett       Date:  2016-10-05       Impact factor: 2.967

4.  Prognostic factors for long-term survival after glioblastoma.

Authors:  Mohammad Sami Walid
Journal:  Perm J       Date:  2008

Review 5.  Glioblastoma multiforme - an overview.

Authors:  Kaja Urbańska; Justyna Sokołowska; Maciej Szmidt; Paweł Sysa
Journal:  Contemp Oncol (Pozn)       Date:  2014-08-04

6.  Overexpression of Tripartite Motif-Containing 48 (TRIM48) Inhibits Growth of Human Glioblastoma Cells by Suppressing Extracellular Signal Regulated Kinase 1/2 (ERK1/2) Pathway.

Authors:  Li-Ping Xue; Bin Lu; Bi-Bo Gao; Yang-Yang Shi; Jing-Qi Xu; Rui Yang; Bo Xu; Peng Ding
Journal:  Med Sci Monit       Date:  2019-11-08

7.  Inhibition of Proliferation by Knockdown of Transmembrane (TMEM) 168 in Glioblastoma Cells via Suppression of Wnt/β-Catenin Pathway.

Authors:  Jie Xu; Zhongzhou Su; Qiuping Ding; Liang Shen; Xiaohu Nie; Xuyan Pan; Ai Yan; Renfu Yan; Yue Zhou; Liqin Li; Bin Lu
Journal:  Oncol Res       Date:  2019-03-25       Impact factor: 5.574

Review 8.  Delineation of radiation therapy target volumes for patients with postoperative glioblastoma: a review.

Authors:  Fen Zhao; Minghuan Li; Li Kong; Guoli Zhang; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-05-27       Impact factor: 4.147

9.  Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients.

Authors:  Nilgun Ozbek Okumus; Bilge Gursel; Deniz Meydan; Ozge Ozdemir; Eylem Odabas; Guzin Gonullu
Journal:  Ann Saudi Med       Date:  2012 May-Jun       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.